Just a quick review from 1 Nov to date, didn't see anything of value removed. The 510k discussion about the FDA reviewers being on vacation turned out to be false. ARTH got the feedback from the FDA. So now they have (and have had imo) an educated path to follow. I'll have to review the BOD and advisors again to refresh if any of them really do have a clue on how to get things through to market. May be a good idea to bring their third party closer under their wing too.
News 
Market Data 
Discover 
